Oramed Pharmaceuticals Files 8-K for 'Other Event' and Exhibits
Ticker: ORMP · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.012 |
| Sentiment | neutral |
Sentiment: neutral
Topics: other-event, regulatory-filing
TL;DR
**Oramed just dropped an 8-K for an 'Other Event' and exhibits, so keep an eye out for what's next!**
AI Summary
Oramed Pharmaceuticals Inc. filed an 8-K on February 20, 2024, to report an 'Other Event' and 'Financial Statements and Exhibits'. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, with the earliest event reported also on February 20, 2024. The company's business address is 1185 Avenue of the Americas, Third Floor, New York, New York 10036.
Why It Matters
This filing signals that Oramed Pharmaceuticals has an event or information deemed significant enough to warrant immediate disclosure to investors, potentially impacting future company direction or financial health.
Risk Assessment
Risk Level: medium — The 'Other Event' category is broad and could signify anything from minor operational changes to significant strategic shifts, introducing uncertainty.
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — Registrant
- February 20, 2024 (date) — Date of earliest event reported and filing date
- 1185 Avenue of the Americas, Third Floor, New York, New York 10036 (company) — Principal Executive Offices address
- Section 13 or 15(d) (other) — Securities Exchange Act section
- 001-35813 (other) — Commission File Number
FAQ
What is the purpose of Oramed Pharmaceuticals Inc.'s 8-K filing on February 20, 2024?
The 8-K filing by Oramed Pharmaceuticals Inc. on February 20, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
What is the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 20, 2024.
Where are Oramed Pharmaceuticals Inc.'s principal executive offices located?
Oramed Pharmaceuticals Inc.'s principal executive offices are located at 1185 Avenue of the Americas, Third Floor, New York, New York 10036.
What is Oramed Pharmaceuticals Inc.'s Commission File Number?
Oramed Pharmaceuticals Inc.'s Commission File Number is 001-35813.
Under which sections of the Securities Exchange Act of 1934 was this report filed?
This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 10.9 · Accepted 2024-02-20 08:42:26
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, T
Filing Documents
- ea0200197-8k_oramed.htm (8-K) — 32KB
- ea0200197ex99-1_oramed.htm (EX-99.1) — 19KB
- 0001213900-24-015108.txt ( ) — 226KB
- ormp-20240220.xsd (EX-101.SCH) — 3KB
- ormp-20240220_lab.xml (EX-101.LAB) — 33KB
- ormp-20240220_pre.xml (EX-101.PRE) — 22KB
- ea0200197-8k_oramed_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO February 20, 2024 2